<DOC>
	<DOCNO>NCT02215759</DOCNO>
	<brief_summary>Evaluation safety , tolerability pharmacokinetics multiple rise oral dos BI 44370 TA healthy male female volunteer</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Multiple Rising Oral Doses BI 44370 TA Tablets Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female accord follow criterion base upon complete medical history , include physical examination , vital sign , 12lead ECG , clinical laboratory test Age ≥21 Age ≤50 year BMI ≥18.5 BMI ≤29.9 kg/m2 ( Body Mass Index ) Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include vital sign ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoking ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 40 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalaemia , family history Long QT Syndrome ) Exclusion criterion male subject : Not willing use adequate contraception ( condom plus another form contraception e.g . spermicide , oral contraceptive take female partner , sterilisation , intrauterine device ) whole study period time first intake study drug three month last intake Exclusion criterion female subject : Pregnancy plan become pregnant within 3 month study completion Positive pregnancy test No adequate contraception , e.g . implant , injectables , combine oral contraceptive , surgical sterilisation ( include hysterectomy bilateral ovariectomy ) , intrauterine device , use adequate method contraception least three month prior participation study , willing able use adequate contraception three month last intake study drug Lactation</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>